🎉 M&A multiples are live!
Check it out!

Immix Biopharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Immix Biopharma and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Immix Biopharma Overview

About Immix Biopharma

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.


Founded

2012

HQ

United States of America
Employees

21

Website

immixbio.com

Financials

LTM Revenue n/a

LTM EBITDA -$22.9M

EV

$28.6M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Immix Biopharma Financials

Immix Biopharma has a last 12-month revenue of n/a and a last 12-month EBITDA of -$22.9M.

In the most recent fiscal year, Immix Biopharma achieved revenue of n/a and an EBITDA of -$22.6M.

Immix Biopharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Immix Biopharma valuation multiples based on analyst estimates

Immix Biopharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$15.6M -$22.6M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$8.2M -$15.4M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Immix Biopharma Stock Performance

As of April 15, 2025, Immix Biopharma's stock price is $2.

Immix Biopharma has current market cap of $45.2M, and EV of $28.6M.

See Immix Biopharma trading valuation data

Immix Biopharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$28.6M $45.2M XXX XXX XXX XXX $-0.77

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Immix Biopharma Valuation Multiples

As of April 15, 2025, Immix Biopharma has market cap of $45.2M and EV of $28.6M.

Immix Biopharma's trades at n/a LTM EV/Revenue multiple, and -1.2x LTM EBITDA.

Analysts estimate Immix Biopharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Immix Biopharma and 10K+ public comps

Immix Biopharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $28.6M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -1.3x XXX XXX XXX
P/E -2.1x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -1.8x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Immix Biopharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Immix Biopharma Valuation Multiples

Immix Biopharma's NTM/LTM revenue growth is n/a

Immix Biopharma's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.1M for the same period.

Over next 12 months, Immix Biopharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Immix Biopharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Immix Biopharma and other 10K+ public comps

Immix Biopharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 45% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Immix Biopharma Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Immix Biopharma M&A and Investment Activity

Immix Biopharma acquired  XXX companies to date.

Last acquisition by Immix Biopharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . Immix Biopharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Immix Biopharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Immix Biopharma

When was Immix Biopharma founded? Immix Biopharma was founded in 2012.
Where is Immix Biopharma headquartered? Immix Biopharma is headquartered in United States of America.
How many employees does Immix Biopharma have? As of today, Immix Biopharma has 21 employees.
Who is the CEO of Immix Biopharma? Immix Biopharma's CEO is Dr. Ilya Rachman.
Is Immix Biopharma publicy listed? Yes, Immix Biopharma is a public company listed on NAS.
What is the stock symbol of Immix Biopharma? Immix Biopharma trades under IMMX ticker.
When did Immix Biopharma go public? Immix Biopharma went public in 2021.
Who are competitors of Immix Biopharma? Similar companies to Immix Biopharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Immix Biopharma? Immix Biopharma's current market cap is $45.2M
What is the current EBITDA of Immix Biopharma? Immix Biopharma's last 12-month EBITDA is -$22.9M.
What is the current EV/EBITDA multiple of Immix Biopharma? Current EBITDA multiple of Immix Biopharma is -1.2x.
Is Immix Biopharma profitable? Yes, Immix Biopharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.